Concepedia

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Mathias Rummel, S. Al-Batran, Soo-Z. Kim, Manfred Welslau, Ralf Hecker, Dorothea Kofahl-Krause, Klaus-M. Josten, Heinz Dürk, A. Rost, Michael Neise,

Journal of Clinical Oncology · 2005 · 439 citations · 18 references

DOIFull text

Open access

Abstract

These results demonstrate that the BR combination is a highly active regimen in the treatment of low-grade lymphomas and mantle cell lymphomas.

References

18

A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

New England Journal of Medicine · 1993 · 4.9K citations · Full text

A predictive model for aggressive non-Hodgkin's lymphoma

Margaret A. Shipp, David P. Harrington, J R Anderson et al. · 1993 · 3.5K citations

, , +5

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

ME Reff, K Carner, KS Chambers et al. · Blood · 1994 · 1.9K citations · Full text

IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

David G. Maloney, Antonio J Grillo-López, Christine A. White et al. · Blood · 1997 · 1.7K citations

Follicular Lymphoma International Prognostic Index

Blood · 2004 · 1.5K citations · Full text